Aurobindo Pharma Ltd. (NSE: AUROPHARMA) and Mankind Pharma (NSE: MANKIND) are both listed in the Medicinal Chemicals and Botanical Products industry. Aurobindo Pharma has a market capitalisation of ₹96,882 Cr and Mankind Pharma ₹1,02,485 Cr, as of 9 Nov 2026. Their P/E ratios are 27.9 and 53.6 respectively. Return on equity is 9.93% for Aurobindo Pharma and 12.45% for Mankind Pharma. Over one year, Aurobindo Pharma's share price is up 62.9% and Mankind Pharma's is up 11.2%.
| Metric | Aurobindo Pharma | Mankind Pharma |
|---|---|---|
| NSE Symbol | AUROPHARMA | MANKIND |
| BSE Code | 524804 | 543904 |
| Share Price | ₹1,855.30 | ₹2,668.30 |
| Market Cap | ₹96,882 Cr | ₹1,02,485 Cr |
| P/E Ratio | 27.9 | 53.6 |
| Return on Equity | 9.93% | 12.45% |
| Return on Assets | 5.95% | 6.31% |
| Dividend Yield | 0.00% | 0.08% |
| Beta (1Y) | 0.14 | 0.43 |
| 1-Year Price Change | +62.9% | +11.2% |
| 3-Month Price Change | +12.6% | +9.4% |
| 52-Week Range | ₹1,106.00 – ₹1,856.10 | ₹1,909.70 – ₹2,705.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹10,263 Cr | ₹4,338 Cr |
| Quarterly Net Profit | ₹1,124 Cr | ₹716 Cr |
| Net Margin | 11.0% | 16.5% |
| EPS (Basic, Quarter) | ₹19.57 | ₹17.23 |
| Results Basis | consolidated | consolidated |
| Headquarters | Hyderabad, Telangana | New Delhi, Delhi |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HI…
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations…
Mankind Pharma has a market capitalisation of ₹1,02,485 Cr, against ₹96,882 Cr for Aurobindo Pharma as of 9 Nov 2026, so the two are about the same size by market cap.
Aurobindo Pharma has a P/E of 27.9 and Mankind Pharma a P/E of 53.6 as of 9 Nov 2026.
Aurobindo Pharma has a return on equity of 9.93% and Mankind Pharma 12.45%.
Aurobindo Pharma's share price is up 62.9% over one year and Mankind Pharma's is up 11.2%.
Aurobindo Pharma reported revenue of ₹10,263 Cr and net profit of ₹1,124 Cr for Q2 FY27. Mankind Pharma reported revenue of ₹4,338 Cr and net profit of ₹716 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.